References analysis of the Wikipedia article "Хороидална неоваскуларизација" in the Serbian version

doi.org

Moulton, K. S.; Vakili, K.; Zurakowski, D.; Soliman, M.; Butterfield, C.; Sylvin, E.; Lo, K. M.; Gillies, S.; Javaherian, K.; Folkman, J. (2003). „Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis”. PNAS. 100 (8): 4736—4741. Bibcode:2003PNAS..100.4736M. PMC 153625 

. PMID 12682294. doi:10.1073/pnas.0730843100 

Friedman, D. S.; O'Colmain, B. J.; Muñoz, B.; Tomany, S. C.; McCarty, C.; De Jong, P. T.; Nemesure, B.; Mitchell, P.; Kempen, J.; Eye Diseases Prevalence Research Group (2004). „Prevalence of age-related macular degeneration in the United States”. Archives of Ophthalmology. 122 (4): 564—72. PMID 15078675. doi:10.1001/archopht.122.4.564.

Chakravarthy U.; Soubrane G.; Bandell, F.; et al. (2006). „Evolving European guidance on the medical managment of neovascular age-related macular degeneratin”. Br J Ophthalmol. 90 (9): 1188—1196. PMC 1857411 

. PMID 16929063. doi:10.1136/bjo.2005.082255..

White, F.; Carroll, S.; Magnet, A.; et al. (1992). „Coronary collateral development in swine after coronary arteryocclusion.”. Circ Res. 71 (6): 1490—1500. PMID 1423941. doi:10.1161/01.RES.71.6.1490.

Wolf, C.; Cai, W. J.; Vosschulte, R.; et al. (1998). „Vascular remodeling and altered protein expression during growth of coronary collateral arteries.”. J Mol Cell Cardiol. 30 (11): 2291—2305. PMID 9925366. doi:10.1006/jmcc.1998.0790.

Gibson, C. M.; Ryan, K.; Sparano, A.; et al. (1999). „Angiographic methods to assess human coronary angiogenesis.”. American Heart Journal. 137 (1): 169—179. PMID 9878950. doi:10.1016/S0002-8703(99)70473-4.

Sasayama, S.; Fujita, M. (1992). „Recent insights into coronary collateral circulation”. Circulation. 85 (3): 1197—1204. PMID 1371432. doi:10.1161/01.CIR.85.3.1197.

Ito, W.; Arras, M.; Scholz, D.; et al. (1997). „Angiogenesis but not collateral growth is associated with ischemia after femoral artery occlusion”. Am J Physiol. 273 (3 Pt 2): H1255—H1265. PMID 9321814. doi:10.1152/ajpheart.1997.273.3.H1255.

Li, J.; Post, M.; Volk, R.; et al. (2000). „PR39, a peptide regulator of angiogenesis”. Nature Medicine. 6 (1): 49—55. PMID 10613823. doi:10.1038/71527.

Jones, M. K.; Wang, H.; Peskar, B. M.; et al. (1999). „Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing [see comments].”. Nature Medicine. 5 (12): 1418—1423. PMID 10581086. doi:10.1038/70995.

Rosenfeld P.J., Moshfeghi A.A and Puliafito C.A. (2005). „Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration”. Ophthalmic Surg Lasers Imaging. 36 (4): 331—35. PMID 16156152. doi:10.3928/1542-8877-20050701-14..

Gragoudas, E. S.; Adamis, A. P.; Cunningham Jr, E. T.; Feinsod, M.; Guyer, D. R.; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004). „Pegaptanib for neovascular age-related macular degeneration”. New England Journal of Medicine. 351 (27): 2805—16. PMID 15625332. doi:10.1056/NEJMoa042760.

Rosenfeld, P. J.; Brown, D. M.; Heier, J. S.; Boyer, D. S.; Kaiser, P. K.; Chung, C. Y.; Kim, R. Y.; MARINA Study Group (2006). „Ranibizumab for neovascular age-related macular degeneration”. New England Journal of Medicine. 355 (14): 1419—31. PMID 17021318. doi:10.1056/NEJMoa054481.

Brown, D. M.; Kaiser, P. K.; Michels, M.; Soubrane, G.; Heier, J. S.; Kim, R. Y.; Sy, J. P.; Schneider, S.; ANCHOR Study Group (2006). „Ranibizumab versus verteporfirin for neovascular agerelated macular degeneration”. New England Journal of Medicine. 355 (14): 1432—44. PMID 17021319. doi:10.1056/NEJMoa062655.

Rosenfeld, P. J. (2006). „Intravitreal avastin: The low cost alternative to lucentis?”. American Journal of Ophthalmology. 142 (1): 141—43. PMID 16815262. doi:10.1016/j.ajo.2006.03.036.

Stone E.M. (2006). „A very effective treatment for neovascular maculardegeneration”. New England Journal of Medicine. 355 (14): 1493—95. PMID 17021326. doi:10.1056/NEJMe068191..

Rich R.M.; Rosenfeld P.J.; Puliafito C.A; et al. (2006). „Short-time safetyand efficacy of intravitreal bevacizumab (Avastin) forneovascular age-realted macular degeneration”. Retina. 26 (5): 495—511. PMID 16770255. doi:10.1097/01.iae.0000225766.75009.3a..(abstract)

Spaide R.F.; Laud K.; Fine H.F; et al. (2006). „Intravitreal bevacizumabtreatment of choroidal neovascularization secondary toage-related macular degeneration”. Retina. 26 (4): 383—90. PMID 16603955. doi:10.1097/01.iae.0000238561.99283.0e.(abstract)

Avery, R. L.; Pieramici, D. J.; Rabena, M. D.; Castellarin, A. A.; Nasir, M. A.; Giust, M. J. (2006). „Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration”. Ophthalmology. 113 (3): 363—372.e5. PMID 16458968. doi:10.1016/j.ophtha.2005.11.019.

Bashshur Z.F.; Bazarbachi A.; Schakal, A.; et al. (2006). „IntravitrealBevacizumab for the management of choroidal neovascularisationin age-related macular degeneration”. American Journalof Ophthalmology. 142 (1): 1—9. PMID 16815245. doi:10.1016/j.ajo.2006.02.037..

Meyer C.H., Mennel S., Schmidt J.C., Kroll P. (2006). „Acute retinal pigment epithelial tear following intravitreal bevaciyumab (Avastin) injection for occult choroidal neovascularization secondary to age-related macular degeneration”. Br J Ophthalmol. 90 (9): 1207—08. PMC 1857397 

. PMID 16929069. doi:10.1136/bjo.2006.093732..

Manzano R.P.A.; Peymen G.A.; Khan, P.; et al. (2006). „Testing intravitrealtoxicity of bevacizumab (Avastin)”. Retina. 26 (3): 257—61. PMID 16508423. doi:10.1097/00006982-200603000-00001.. (Аbstract)

Luthra S.; Narayanan R.; Marques L.E; et al. (2006). „Evaluation of invitro effects of bevacizumab (Avastin) on retinal pigment epithelial,neurosesory retinal and microvascular endothelialcells”. Retina. 26 (5): 512—18. PMID 16770256. doi:10.1097/01.iae.0000222547.35820.52..

Spitzer M.S.,Wallenfels Thilo B., Sierra A; et al. (2006). „Antiproliferativeand cytotxic properties of bevacizumab on differentocular cells”. Br J Ophthalmol. 90 (10): 1316—21. PMC 1857456 

. PMID 16723358. doi:10.1136/bjo.2006.095190..

Bakri S.J.; Cameron J.D.; McCannel C.A; et al. (2006). „Abscence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model”. American Journal of Ophthalmlogy. 142 (1): 162—64. PMID 16815270. doi:10.1016/j.ajo.2006.03.058.

Ziemssen F.; Neuhann I.M.; Leitritz M.; et al. (2006). „Does intravitreal injection of bevacizumab have an effect on the blood-aques barrier function”. Br J Ophthalmol. 90 (7): 922. PMC 1857155 

. PMID 16782958. doi:10.1136/bjo.2006.092262.

Grisanti S.; Biester S.; Peters, S.; et al. (2006). „Intracameral Bevacizumabfor iris rubeosis”. American Journal of Ophthalmology. 142 (1): 158—60. PMID 16815268. doi:10.1016/j.ajo.2006.02.045..

Davidorf F.H.; Mouser J.G.; Derick R.J. (2006). „Rapid improvementof rubeosis iridis from a single bevacizumab (Avastin) injection”. Retina. 26 (3): 354—56. PMID 16508439. doi:10.1097/00006982-200603000-00017..

nih.gov

ncbi.nlm.nih.gov